Pramod Kumar Srivastava

Pramod Kumar Srivastava (an haife shi a ranar 15 ga watan Agustan shekara ta 1955) Masanin rigakafi ne na Amurka kuma likita ne wanda ke aiki a matsayin shugaban Eversource Energy a gwajin oncology a Jami'ar Connecticut School of Medicine . An san shi da aikinsa a kan Allurar rigakafin cutar kansa.

Shi ne wanda ya kafa kimiyya na Antigenics (AGEN), kamfanin biotech na New York.

 Rayuwa ta farko da ilimi 
Srivastava ya kammala Ph.D. a Cibiyar Cellular da Molecular Biology, Hyderabad, Indiya, da kuma MD daga Jami'ar Connecticut School of Medicine .  

 Ayyuka 
An nada Srivastava Mataimakin Farfesa a Sashen Farfesa, Makarantar Kiwon Lafiya ta Dutsen Sinai, a shekarar 1989. Ya koma Jami'ar Fordham a matsayin mataimakin farfesa a fannin ilmin halitta a 1993 kuma ya zama cikakken Farfesa a 1995. A wannan lokacin, Srivastava ya kafa kamfanin biotechnology, Antigenics, a cikin 1994. 

A shekara ta 1997, an nada shi farfesa a fannin kiwon lafiya a Jami'ar Connecticut School of Medicine . Ya zama darektan da ya kafa Cibiyar Immunotherapy na Ciwon daji da Cututtukan Cututtuka. Ya kuma kasance shugaban kafa Sashen Immunology. Tun daga shekara ta 2011, ya kasance darektan Cibiyar Ciwon daji ta Carole da Neag a Makarantar Kiwon Lafiya ta Jami'ar Connecticut . 

 Ayyukan kimiyya da na asibiti 
Srivastava ya ba da gudummawa ga Neuroimmunology. Gidan gwaje-gwaje na farko ya gano masu karɓar zafin jiki (masu karɓar TRPV) a kan sel na dendritic kuma ya ba da rahoton sakamakon haɗin waɗannan masu karɓa akan haƙurin rigakafi a cikin hanji. Bugu da kari, Srivastava yayi bincike kan hulɗar neuroimmunology kuma ya nuna yadda Tsarin juyayi na tausayi yake da mahimmanci ga ci gaban neutrophils na yau da kullun kuma cewa dysregulation na wannan hanyar yana haifar da ƙarni na ƙwayoyin masu hana rigakafi na myeloid, wanda ke inganta yaduwa Kwayoyin T masu sarrafawa.[1]

 Littattafai 
Srivastava tana da littattafai sama da 200 da aka sake dubawa da kuma takardun shaida sama da 200 a fannin rigakafin cutar kansa ciki har da:

 Binciken juyawa ya nuna rigakafin rigakafi na MHC I-binding cancer neoepitope. Doi: https://doi.org/10.1038/s41467-021-26646-5

 Hanyar da ba ta da son kai don bayyana ainihin ciwon daji neoepitopes wanda ke haifar da ƙin cutar kansa ta hanyar rigakafi. Doi: https://doi.org/10.1172/jci142823

 Sautin jijiya mai tausayi yana iyakance ci gaban ƙwayoyin ƙwayoyin cuta na Doi: https://doi.org/10.1126/sciimmunol.aay9368

 Cross-dressing na CD8α+ Dendritic Cells tare da Antigens daga Live Mouse Tumor Cells Babban Hanyar Cross-priming Doi ne: https://doi.org/10.1158/2326-6066.cir-20-0248

 Manazarta 

Rukuni:Haifaffun 1955
Rukuni:Rayayyun mutane
Rukuni:Shafuka masu fassarorin da ba'a duba ba